2717 Partners

Managing Members Fred Dwek and Michael Weiss lead day-to-day investment and operational decisions alongside Chairman Lindsay Rosenwald. Rosenwald acts as the originating force for the overall pipeline and syndicate relationships, while Dwek and Weiss handle structuring, legal execution, and portfolio company oversight. The three have worked together across multiple predecessor entities spanning more than two decades.

2717 Partners shares management and strategic DNA with Fortress Biotech, which Lindsay Rosenwald co-founded and where Michael Weiss served as Executive Vice Chairman and interim CEO. Both entities develop internally incubated biotech companies, though 2717 Partners operates as a distinct partnership series with its own capital base and portfolio construction approach. The crossover reflects the principals' long-standing practice of launching successive vehicles under different banners.

The firm licenses molecules from academic medical centers, research hospitals, and government laboratories — past sources include the National Institutes of Health and Memorial Sloan Kettering. Rosenwald's decades-long network in oncology research provides a proprietary origination funnel that bypasses the competitive auction processes typical of larger biotech venture funds. The group then recruits specialized management teams for each company.